Article

The role of EPHA3 mutation in the prognosis of non-small cell lung cancer patients receiving immunotherapy

2024-06-12

Abstract excerpt

<title>Abstract</title> <p>Background Immune checkpoint inhibitors (ICIs) have changed the treatment mode of non-small cell lung cancer (NSCLC) patients, but precise biomarkers are still needed to screen out those who could benefit from ICIs. EPHA3 is the gene that codes for the Eph receptor A3 and has been found to be associated with lung cancer, but the relationship between EPHA3 and ICIs still needs to be exp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 92432b62-f3f0-564d-b0c6-7695877de519
DOI: 10.21203/rs.3.rs-4231810/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The role of EPHA3 mutation in the prognosis of non-small cell lung cancer patients receiving immunotherapyDOI 10.21203/rs.3.rs-4231810/v1Read

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.Semantic proximity Read

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinomaSemantic proximity Read

EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.Semantic proximity Read

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.Semantic proximity Read

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.Semantic proximity Read

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.Semantic proximity Read

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read

UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer.Semantic proximity Read

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read

Systematic Pan-Cancer Analysis Reveals the Prognostic Value and Immunological Role of EPHX2Semantic proximity Read

EFNA3 Can Serve as Potential Prognostic Biomarker for Luad Patients: A Comprehensive Analysis of the Eph/Ephrin  FamilySemantic proximity Read

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.Semantic proximity Read